Skip to content

PolitiKit

Lobbying by Ipsen Biopharmaceuticals Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Ipsen Biopharmaceuticals Canada Inc.

Meetings this Parliament
0
With MPs
0
Since Nov 2021
0
Active registrations
1

Registrations in effect

Consultant In effect since Jun 15, 2026

Consultant William Dempster of 3Sixty Public Affairs Inc.

Consultant lobbyists

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

  • William Dempster Former public office holder

    Formerly Assistant, Office of the Hon. Irwin Cotler, MP, House of Commons (2002–2003)

Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (11)
  • Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
  • Regulations regarding the exportation of medicines packaged and labelled for the Canadian market to countries other than Canada.
  • Patent Act and Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property and approval for therapeutic products.
  • National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases and incentives for development of the treatments for rare diseases.
  • Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities in Canada.
  • Food and Drugs Act Modernization initiative, including the Regulatory Review of Drugs and Devices.
  • Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products.
  • Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products.
  • Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade.
  • Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
  • Common Drug Review and the pan-Canadian Oncology Drug Review, as they relate to health technology assessments and drug product reimbursement recommendations.

Registration 778465-365067-8. Look it up in the official Registry

Reported meetings

No meetings reported since November 2021.

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.